XML 58 R40.htm IDEA: XBRL DOCUMENT
v3.23.1

Shareholders' Equity (Details) $ / shares in Units, € in Thousands, $ in Thousands |  |  |  |  |  | 1 Months Ended | 4 Months Ended | 10 Months Ended | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 03, 2022 | Sep. 13, 2022 | May 11, 2022 | Apr. 04, 2022 $ / shares shares | Jan. 04, 2018 $ / shares shares | Jan. 25, 2023 shares | Mar. 31, 2022 USD ($) shares | Jan. 31, 2022 USD ($) | Jul. 01, 2021 ₪ / shares shares | Oct. 31, 2020 $ / shares shares | Jan. 22, 2020 | Jan. 19, 2020 $ / shares | Mar. 19, 2019 USD ($) $ / shares shares | Nov. 30, 2018 USD ($) $ / shares | May 31, 2018 shares | Jan. 24, 2018 | Sep. 30, 2017 USD ($) | Aug. 31, 2016 USD ($) | May 31, 2018 USD ($) | Nov. 02, 2018 USD ($) shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2022 EUR (€) shares | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) shares | Jun. 30, 2021 shares | May 31, 2019 shares | May 01, 2019 shares | Apr. 30, 2019 shares | Apr. 06, 2019 shares | Mar. 31, 2019 shares | Jul. 11, 2018 shares
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  |  |  | $ 10 | $ 1,000 |  |  |  |  |  |  |  |  |  | $ 1,960 | $ 2,511 |  | $ 15,647 |  |  |  |  |  |  |  |  |  |
Aggregate shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,465,992 |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.36 |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  | 242,131 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 127,000 |  |  |  |  |  |
Ordinary shares exercised amount |  |  |  |  |  |  | 1,672 |  |  |  |  |  | 470,000 |  |  |  |  |  |  |  |  |  |  |  | 20,724 |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,192 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price per share (in Dollars per share) | $ / shares |  |  |  |  | $ 6.14 |  |  |  |  | $ 6.14 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 184,844 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 510,752 | 510,752 |  |  |  |  |  |  |  |  |
Invested agreement (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  | $ 9,941 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate number of shares |  |  |  |  |  |  |  |  |  |  |  |  | 1,803,296 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Company at a price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 5.54 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  | $ 4.13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5.54 |  |  |  |  |  |  |  |  |  |
Warrants percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% | 20.00% |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  | 242,131 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,332,352 | 2,332,352 |  |  |  |  |  |  |  |  |
Net proceeds (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 13,587 |  |  |  |  |  |  |  |  |  |
Percentage of number of ordinary shares and warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% | 15.00% |  |  |  |  |  |  |  |  |
Purchase ordinary shares |  |  |  |  | 98,120 |  |  |  | 195,448 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70.00% | 70.00% |  |  |  |  |  |  |  |  |
Risk free interest rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.40% | 1.40% |  |  |  |  |  |  |  |  |
Dividend yields |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.00% | 0.00% |  |  |  |  |  |  |  |  |
Weighted average life |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years | 5 years |  |  |  |  |  |  |  |  |
Exercise price per share | (per share) |  |  |  |  |  |  |  |  | ₪ 0.01 |  |  | $ 0.003 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortized over |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 196 |  | $ 331 |  |  |  |  |  |  |  |
Option exercise price (in Dollars per share) | $ / shares |  |  |  |  | $ 6.1393 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average fair value of options granted per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.479 |  |  |  |  |  |  |  |  |  |
Share-based payment expenses related to nonvested awards (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 498 |  |  |  |  |  |  |  |  |  |
Expected term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years 9 months | 2 years 9 months |  |  |  |  |  |  |  |  |
Granted options shares |  |  |  |  |  |  |  |  |  | 139,216 |  |  |  |  |  |  |  |  |  |  | 1,672 | 1,672 | 20,724 |  |  |  |  |  |  |  |
Options expire term |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense (in Dollars) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125 | € 110 |  | $ 409 |  |  |  |  |  |  |
Termination amount (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 9 |  |  |  |  |  |  |  |
Options granted, description |  | i)On September 13, 2022 the Company granted 252,000 options to its employees at an exercise price of $1.85 per share. These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on September 13, 2023 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. For the years ended December 31, 2022, the Company recorded an expense of $10, in respect for such grant. | the Company granted to four of its directors’ options to purchase 119,796 ordinary shares and 39,932 ordinary shares, respectively, with an exercise price of $1.85 per share. Such options will vest one-third following 12 months from the grant date of such options, second one-third following 24 months from the grant date and the balance following 36 months. For the year ended December 31, 2022, the Company recorded an expense of $17 in respect for such grant. |  |  |  |  |  |  | (1) options to purchase 139,205 ordinary shares vested in one tranche at the end of 12 months from October 13, 2020; and (2) options to purchase 278,410 ordinary shares will vest in the event that the Company generate a cumulative order backlog (as defined in the option agreement) in the amount of not less than $7,000 by the end of 18 months from October 13, 2020; (3) options to purchase 139,205 ordinary shares will vest in the event that the Company reaches a cumulative order backlog of $15,000 by the end of 24 months from October 13, 2020 (including the first cumulative order backlog); and all subject to him serving as the active Chairman of the Company’s Board at the time of vesting. | the Company granted options to purchase 671,308 ordinary shares to its employees at an exercise price of $6.14 per share (of which options to purchase 74,580 ordinary shares were to the Company’s former CEO that were forfeited at the end of his employment in December 2020). These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on September 18, 2020 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. For the years ended December 31, 2022, 2021 and 2020, the Company recorded an expense of $163, $380 and $812, respectively, in respect for such grant. |  |  |  |  | b)On June 24, 2018, the Company granted options to purchase 188,100 ordinary shares to its employees and directors at an exercise price of $6.14 per share. These options expire 10 years after their grant date and vest over three years in nine tranches. One third of the options vested upon the first-year anniversary and the reminder vested in eight equal quarterly tranches over a period of two years thereafter. For the years ended December 31, 2021 and 2020, the Company recorded an expense of $89 and $303, respectively, in respect for such grant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unvested options percentage |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vested shares |  |  |  |  |  |  |  |  |  | 139,216 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 278,410 | 278,410 |  |  |  |  |  |  |  |  |
Recorded an expense (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 133 |  | $ 332 | $ 199 |  |  |  |  |  |  |
KB Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 655,732 |  |  |  |  |  |  |  |  |  |
October 2020 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options granted, description |  |  |  |  |  |  |  |  |  | the Company granted to its CEO options to purchase 61,600 ordinary shares at an exercise price of $6.14 per share vest as follows: (1) options to purchase 30,800 ordinary shares will vest on the condition that the Company generates, no later than October 12, 2022, a cumulative order backlog (as defined in the option agreement) in an amount not less than $10,000; and (2) options to purchase the remaining 30,800 ordinary shares will vest on the condition that the Company generates, no later than October 12, 2024 a cumulative order backlog (as defined above) in an amount not less than $20,000 (including the first cumulative order backlog); and all subject to him serving in his position at the time of vesting.As of December 31, 2022, a total of 30,800 of the CEO’s options has expired as the period of 24 months has passed and the Company did not reach the required cumulative order backlog, as detailed above. For the years ended December 31, 2022, 2021 and 2020, the Company recorded an expense of $20, $12 and $12 , respectively, in respect for such grant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
November 3, 2020 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options granted, description | f)On November 3, 2020, the Company granted options to purchase 107,800 ordinary shares to its employees at an exercise price of $6.14 per share. These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on November 3, 2021, and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. For the years ended December 31, 2022, 2021 and 2020, the Company recorded an expense of $46, $62 and $14, respectively, in respect for such grant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
May 11 ,2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options granted, description |  |  | g)On May 11, 2022, the Company granted to three officers options to purchase 547,162 ordinary shares including 266,216 to its former chairman of the Board, 156,081 to its CEO and 124,865 to its CFO, at an exercise price of $1.85 per share (equal to the average closing share price on the Nasdaq over the first 30 calendar days following the IPO on April 4, 2022). These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on May 11, 2023 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. For the years ended December 31, 2022. The Company recorded an expense of $61, in respect for such grant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 13,2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options granted, description |  | j)On September 13, 2022 the Company granted 100,000 options to two of its officers at an exercise price of $1.85 per share. These options expire 10 years after their grant date and vest in twelve equal quarterly tranches over a period of three years. For the years ended December 31, 2022, the Company recorded an expense of $4, in respect for such grant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IPO [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issued price per share (in Dollars per share) | $ / shares |  |  |  | $ 3,787,241 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, description |  |  |  | Each unit includes one ordinary share and one warrant to purchase one ordinary share at an exercise price of $4.13. The warrants are exercisable at any time up to five years after the IPO. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Over-Allotment Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase ordinary shares |  |  |  | 568,086 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series A [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,158 |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,135,572 | 3,135,572 |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,639,000
Series B [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,135,572 | 3,135,572 |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 234,608 | 1,281,456 |  |  |  |
Ordinary shares exercised amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,411,000 |  |  |  |
Series C [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,158 |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,135,572 | 3,135,572 |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,639,000
Ordinary shares expired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,732 |  |  |  |  |  |  |  |  |  |  |
Series D [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  | 214,500 |  |  |  |  |  |  |  | 951,676 |  |  |  |  |  |  |  |  | 81,884 |
Ordinary shares exercised amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,711,000 |  |
Exercise price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6.14 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series E [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 951,676 |  |  |  |  |  |  |  | 303,512 | 434,016 |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  |  |  | 195,448 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options to employees [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage weighted average volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 68.00% |  |  |  |  |  |  |  |  |  |
Dividend yields |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.00% | 0.00% |  |  |  |  |  |  |  |  |
Options expired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years | 6 years |  |  |  |  |  |  |  |  |
Options to employees [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk free interest rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.43% | 0.43% |  |  |  |  |  |  |  |  |
Options to employees [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk free interest rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.83% | 2.83% |  |  |  |  |  |  |  |  |
Two Thousand Seventeen Plan [Member] | September 13,2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options granted, description |  | in accordance with the terms of the 2017 Plan, the Board approved a modification of 375,716 outstanding options held by officers and employees that had an exercise price of $6.14 per share and reduced the exercise price to $1.85 per share. This resolution was effective from November 3, 2022, after receiving approval from the Israeli Tax Authorities. The Company calculated the fair value of such options immediately before and after the modification. The Company immediately recognized the additional fair value attributable to vested options, approximately $51, as share based payment expenses. The additional fair value resulting from the modification, approximately $30, is being expensed over the remaining vesting period of the modified options.The modification of 368,170 additional outstanding options held by the Company’s CEO and two Directors was approved by the Board and is subject to an approval by the Company’s shareholders. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Employees [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted options shares |  |  |  |  | 452,496 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Directors [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted options shares |  |  |  |  | 452,496 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Chief Executive Officer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' Equity (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted options shares |  |  |  |  |  |  |  |  |  | 556,820 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | rvsn_AggregateOrdinaryShares
Namespace Prefix: | rvsn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance of aggregate ordinary shares. + References No definition available. + Details
Name: | rvsn_AggregateSharesIssued
Namespace Prefix: | rvsn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | rvsn_AmortizedOver
Namespace Prefix: | rvsn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_DividendYields
Namespace Prefix: | rvsn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_ExercisePricePerShares
Namespace Prefix: | rvsn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross proceeds. + References No definition available. + Details
Name: | rvsn_GrossProceeds
Namespace Prefix: | rvsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition t is a type of shareholders agreement which serves to regulate the relationships between the founding shareholders who have incorporated or are to incorporate a company and the investor who shall finance their growth. + References No definition available. + Details
Name: | rvsn_InvestedAgreement
Namespace Prefix: | rvsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net proceeds. + References No definition available. + Details
Name: | rvsn_NetProceeds
Namespace Prefix: | rvsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_NumberOfOrdinarySharesAndWarrantsPercentage
Namespace Prefix: | rvsn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_OptionsExpire
Namespace Prefix: | rvsn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_OptionsGrantedDescription
Namespace Prefix: | rvsn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ordinary shares exercised amount. + References No definition available. + Details
Name: | rvsn_OrdinarySharesExercisedAmount
Namespace Prefix: | rvsn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Ordinary shares expired. + References No definition available. + Details
Name: | rvsn_OrdinarySharesExpired
Namespace Prefix: | rvsn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Risk free interest rate. + References No definition available. + Details
Name: | rvsn_RiskFreeInterestRate
Namespace Prefix: | rvsn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rvsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardsFairValueAssumptionsExpectedTerm
Namespace Prefix: | rvsn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment expenses related to non-vesting condition is any condition that does not determine whether the entity receives the services that entitle the counterparty to receive cash, other assets or equity instruments of the entity under a share-based payment arrangement. + References No definition available. + Details
Name: | rvsn_SharebasedPaymentExpensesRelatedToNonvestedAwards
Namespace Prefix: | rvsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_ShareholdersEquityDetailsLineItems
Namespace Prefix: | rvsn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Unvested options percentage. + References No definition available. + Details
Name: | rvsn_UnvestedOptionsPercentage
Namespace Prefix: | rvsn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrants description. + References No definition available. + Details
Name: | rvsn_WarrantsDescription
Namespace Prefix: | rvsn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | rvsn_WarrantsPercentage
Namespace Prefix: | rvsn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rvsn_WarrantsPurchase
Namespace Prefix: | rvsn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate dividends declared during the period for each share of common stock outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 + Details
Name: | us-gaap_CommonStockDividendsPerShareDeclared
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of excess stock shares of an entity that have been sold or granted to shareholders. + References No definition available. + Details
Name: | us-gaap_ExcessStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense or loss included in net income that result in no cash flow, classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_OtherNoncashExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of weighted average cost inventory present at the reporting date when inventory is valued using different valuation methods. + References No definition available. + Details
Name: | us-gaap_PercentageOfWeightedAverageCostInventory
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage rate used to calculate dividend payments on preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 + Details
Name: | us-gaap_PreferredStockDividendRatePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of preferred stock issued as dividends during the period. Excludes stock splits. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_PreferredStockDividendsShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in financing activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -Section 55 -Paragraph 51 -URI https://asc.fasb.org/extlink&oid=123386837&loc=d3e51840-112757 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -Section 55 -Paragraph 50 -URI https://asc.fasb.org/extlink&oid=123386837&loc=d3e51831-112757 Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -Section 55 -Paragraph 52 -URI https://asc.fasb.org/extlink&oid=123386837&loc=d3e51843-112757 + Details
Name: | us-gaap_SaleLeasebackTransactionGrossProceedsFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Rate of weighted-average expected volatility for award under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional shares authorized for issuance under share-based payment arrangement. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Net number of share options (or share units) granted during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of non-vested options forfeited. + References No definition available. + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_StockOptionExercisePriceIncrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 405 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126938292&loc=d3e56288-109415 + Details
Name: | us-gaap_TerminationLoans
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_WarrantExercisePriceDecrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_WarrantExercisePriceIncrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=rvsn_October2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=rvsn_November32020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=rvsn_May112022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=rvsn_September132022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=rvsn_SeriesCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=rvsn_SeriesDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=rvsn_SeriesEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=rvsn_TwoThousandSeventeenPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=rvsn_EmployeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |